Galectin Therapeutics (GALT) Share-based Compensation (2010 - 2026)
Galectin Therapeutics (GALT) posted quarterly Share-based Compensation of $686000.0 for Q1 2026, up 46.58% year-over-year from $468000.0 in Q1 2025, and up 674.45% quarter-over-quarter from $88579.0 in Q4 2025.
Galectin Therapeutics (GALT) Share-based Compensation (2010 - 2026) Analysis & Trends
Galectin Therapeutics' Share-based Compensation history runs 17 years deep, the most recent figure standing at $686000.0 for Q1 2026.
- In Q1 2026, Share-based Compensation rose 46.58% year-over-year to $686000.0; the TTM figure through Mar 2026 stood at $1.7 million (down 13.89% YoY), while the FY2025 annual figure was $1.7 million, down 32.33% from the prior year.
- Share-based Compensation for Q1 2026 stood at $686000.0, up from $88579.0 in the prior quarter.
- The five-year high for Share-based Compensation was $1.0 million in Q2 2025, with the low at $72000.0 in Q1 2024.
- The 5-year median for Share-based Compensation is $515000.0 (2024), against an average of $479257.0.
- The sharpest annual moves came in 2023 and 2025: Share-based Compensation tumbled 86.95% in 2023, then jumped 550.0% in 2025.
- Galectin Therapeutics' Share-based Compensation stood at $178000.0 in 2022, then decreased by 12.17% to $156345.0 in 2023, then soared by 92.17% to $300445.0 in 2024, then sank by 70.52% to $88579.0 in 2025, then jumped by 674.45% to $686000.0 in 2026.
- Business Quant data shows GALT's Share-based Compensation at $686000.0 in Q1 2026, $88579.0 in Q4 2025, and $498000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 277.20 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 137.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 590,899.88 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 86.63 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 41.25 Mn |
| 10 | Galectin Therapeutics | 226.55 Mn | 226.55 Mn | - | 686,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 686,000.00 |
| Mar 31, 2026 | 686,000.00 |
| Dec 31, 2025 | 88,579.00 |
| Dec 31, 2025 | 88,579.00 |
| Sep 30, 2025 | 498,000.00 |
| Sep 30, 2025 | 498,000.00 |
| Jun 30, 2025 | 1.05 Mn |
| Jun 30, 2025 | 1.05 Mn |
| Mar 31, 2025 | 468,000.00 |
| Mar 31, 2025 | 468,000.00 |
| Dec 31, 2024 | 300,445.00 |
| Dec 31, 2024 | 300,445.00 |
| Sep 30, 2024 | 515,000.00 |
| Sep 30, 2024 | 515,000.00 |
| Jun 30, 2024 | 738,000.00 |
| Jun 30, 2024 | 738,000.00 |
| Mar 31, 2024 | 72,000.00 |
| Mar 31, 2024 | 72,000.00 |
| Dec 31, 2023 | 156,345.00 |
| Dec 31, 2023 | 156,345.00 |